Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
7(58%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
1
8%
Ph phase_2
3
25%
Ph phase_3
8
67%

Phase Distribution

1

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
8(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

12

all time

Status Distribution
Active(9)
Completed(3)

Detailed Status

Recruiting7
Completed3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 23 (25.0%)
Phase 38 (66.7%)

Trials by Status

completed325%
recruiting758%
not_yet_recruiting217%

Recent Activity

7 active trials
Showing 5 of 12
recruitingphase_3

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

NCT07493304
recruitingphase_2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

NCT07175428
recruitingphase_3

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
recruitingphase_3

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
recruitingphase_3

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

NCT07410117
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07493304Phase 3

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Recruiting
NCT07175428Phase 2

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Recruiting
NCT07318610Phase 3

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Recruiting
NCT07213778Phase 3

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

Recruiting
NCT07410117Phase 3

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Recruiting
NCT07697599Phase 3

Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)

Not Yet Recruiting
NCT07015905Phase 3

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Recruiting
NCT07430956Phase 3

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

Recruiting
NCT07626411Phase 3

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Not Yet Recruiting
NCT06454630Phase 2

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

Completed
NCT06299111Phase 2

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Completed
NCT06444178Phase 1

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12